" class="no-js "lang="en-US"> Ian Rountree Archives - Medtech Alert
Thursday, February 02, 2023

Breaking News

Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer iCRYO Announces Partnership with Therapeutic Manufacturer, BTL Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease Poseida Therapeutics Announces Board Change Digital Diagnostics and Tamer Healthcare Announce Strategic Partnership in the Kingdom of Saudi Arabia 20Med Therapeutics and CEPI Sign Agreement to Advance ThermoStable Vaccines Technology The World Health Organisation chooses British air purification company, MedicAir, to tackle ‘invisible threat’ in hospitals Jesduvroq Approved by US FDA for Anaemia of Chronic Kidney Disease in Adults on Dialysis Sherlock Biosciences Acquires Sense Biodetection Advancing CRISPR-Based Diagnostics for Consumers

Sort by:

Date

Top Post

NHS To Offer Licensed Cannabis-Based Medicine To Treat Rare Genetic Condition | PTF

NHS To Offer Licensed Cannabis-Based Medicine To Treat Rare Genetic Condition

The NHS will be able to prescribe cannabidiol (Cannabis) to patients with a rare, seizure-causing […]

Read more

Fundraising

 Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing | Pharmtech Focus

Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing

Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery […]

  1. Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

    Appointments

     Read more
  2. iCRYO Announces Partnership with Therapeutic Manufacturer, BTL

    News

     Read more
  3. Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

    Clinical Trials

     Read more
  4. Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease

    Clinical Trials

     Read more
  5. Poseida Therapeutics Announces Board Change

    Appointments

     Read more